Neurocrine Biosciences (NBIX) Gross Margin (2017 - 2026)

Neurocrine Biosciences' Gross Margin history runs 10 years deep, the most recent figure standing at 98.31% for Q1 2026.

• Quarterly Gross Margin fell 9.0% year-over-year to 98.31% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 98.17% (down 35.0% YoY) and the FY2025 annual result came in at 98.18%, down 38.0% from the prior year.
• Gross Margin was 98.31% for Q1 2026 at Neurocrine Biosciences, up from 97.82% in the prior quarter.
• Across five years, Gross Margin topped out at 98.71% in Q3 2024 and bottomed at 76.0% in Q2 2022.
• A 5-year average of 96.94% and a median of 98.35% in 2023 frame the typical range for Gross Margin.
• Annual changes were most pronounced in 2022 — Gross Margin plunged 2293 bps — and 2023, when it soared 2146 bps.
• Neurocrine Biosciences' Gross Margin stood at 98.13% in 2022, then grew by 0 bps to 98.35% in 2023, then climbed by 0 bps to 98.52% in 2024, then retreated by 1 bps to 97.82% in 2025, then gained by 1 bps to 98.31% in 2026.
• Business Quant data shows NBIX's Gross Margin at 98.31% in Q1 2026, 97.82% in Q4 2025, and 98.24% in Q3 2025.